GangaGen Status
The company raised $3.7 million of convertible debt financing from ATEL Capital Group, Regent Trading and Suchad Chiaranussati on September 1, 2017.
Developer of products for the prevention and treatment of bacterial infections that are resistant to antibiotics. The company's lead product is a recombinant protein, P128, that binds to and kills Staphylococcus, including methicillin-resistant strains of S.aureus (MRSA).
Year Founded
2000
Employees
44
RevenueFY 2008
$290 K
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Acquired/Merged (Operating Subsidiary)
-
Financing Status
Private Equity-Backed
GangaGen News and Updates
下肢静脉溃疡治疗市场研究报告按2023 的竞争、销售、收入、市场 ...
挖软件 | December 4, 2023
Small and medium-scale Biopharmaceutical companies venturing ...
Myjoyonline | August 25, 2023
Small and Medium Scale Antibiotic Developers: Challenges they ...
Centre for Science and Environment | August 18, 2023
5 biotech companies to discover in Bangalore
Labiotech.eu | April 24, 2023
Twenty Prolific Years of Life Sciences Startup Ecosystem
BSI bureau | March 1, 2022
GangaGen's Verticals
GangaGen Primary Industry Sector / Group / Code
GangaGen's Trends
GangaGen Metrics
Growth Rate
Majestic Referring Domains
Headquarters
-
HQ Address Line 13279 Emerson
-
HQ CityPalo Alto
-
HQ State/ProvinceCalifornia
-
HQ Post Code94306
-
HQ CountryUnited States
GangaGen's Keywords
mood_badFeed is empty.
Add a review